Global Leading Market Research Publisher QYResearch announces the release of its latest report “Azilsartan Medoxomil API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Azilsartan Medoxomil API market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are pharmaceutical manufacturers, generic drug developers, and API suppliers investing in Azilsartan Medoxomil API for hypertension treatment? Hypertension (high blood pressure) affects 1.3–1.5 billion adults globally, contributing to 10+ million deaths annually from stroke, myocardial infarction, and other cardiovascular events. Traditional antihypertensive agents (ACE inhibitors, calcium channel blockers, diuretics, beta-blockers, and earlier ARBs) have varying efficacy and side effect profiles. Azilsartan medoxomil (trade name Edarbi) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension, reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used alone or in combination with other antihypertensive agents such as chlorthalidone. As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1), blocking the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug – it is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal tract during the absorption phase. The market for Azilsartan Medoxomil API is driven primarily by the global prevalence of hypertension, which continues to rise due to aging populations, sedentary lifestyles, and dietary factors. As a potent ARB, azilsartan medoxomil offers superior blood pressure-lowering efficacy compared to other ARBs (lower systolic blood pressure reduction by 2–5 mmHg vs. olmesartan, valsartan, and irbesartan in clinical trials), fueling its demand in both monotherapy and combination drug formulations.
The global market for Azilsartan Medoxomil API was estimated to be worth US$ 22 million in 2024 and is forecast to reach a readjusted size of US$ 77.5 million by 2031, growing at a CAGR of 20.0% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4923867/azilsartan-medoxomil-api
Product Definition: What Is Azilsartan Medoxomil API?
Azilsartan Medoxomil Active Pharmaceutical Ingredient (API) is a prodrug that is converted in vivo to azilsartan, a selective AT1 receptor antagonist. The chemical structure: C30H24N4O8, molecular weight 568.53 g/mol. The manufacturing process involves multi-step organic synthesis: (a) benzimidazole ring formation – coupling of 4-(2-cyanophenyl)benzoic acid with ethyl 4-aminobenzoate; (b) tetrazole ring formation – conversion of cyano group to tetrazole via azide chemistry; (c) esterification – introduction of medoxomil group (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl; (d) purification – recrystallization and chromatography to achieve >99% purity (pharmaceutical grade). Key quality attributes: purity (≥99% by HPLC), related substances (individual impurity <0.1%, total impurities <0.5%), residual solvents (Class 1 and 2 solvents below ICH limits), heavy metals (<20 ppm), and particle size distribution (for formulation consistency). The API is formulated into tablets (20 mg, 40 mg, 80 mg) for once-daily oral administration. Azilsartan medoxomil is a Biopharmaceutics Classification System (BCS) Class II compound (low solubility, high permeability). The prodrug design improves oral bioavailability compared to direct administration of azilsartan (hydrolysis occurs in GI tract during absorption). The API is supplied in drums (25–50 kg) to pharmaceutical manufacturers for tablet formulation.
Market Segmentation: Purity Level and Tablet Strength
By Purity Level (API Specification):
- 99% Purity – Largest segment (95–98% of market value). Pharmaceutical grade for finished dosage form manufacturing.
- Others – 2–5% of market value (lower purity for R&D, non-pharmaceutical applications).
By Tablet Strength (Finished Dosage Form):
- 20 mg Tablets – 15–20% of market value. Initiation dose, mild hypertension, or dose titration.
- 40 mg Tablets – 35–40% of market value. Standard maintenance dose.
- 80 mg Tablets – 40–45% of market value. Highest dose for patients not controlled on 40 mg.
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The Superior Efficacy Value Proposition
Azilsartan medoxomil offers superior blood pressure-lowering efficacy compared to other ARBs. In head-to-head clinical trials (n=1,200): (a) azilsartan medoxomil 80 mg reduced 24-hour systolic blood pressure (SBP) by 14.5 mmHg vs. olmesartan 40 mg (12.5 mmHg) and valsartan 320 mg (10.5 mmHg); (b) azilsartan medoxomil 40 mg reduced 24-hour SBP by 13.0 mmHg vs. irbesartan 300 mg (11.0 mmHg). The superior efficacy is attributed to tighter binding to the AT1 receptor and longer duration of action (24-hour coverage with once-daily dosing). For patients with moderate-to-severe hypertension (baseline SBP >160 mmHg), azilsartan medoxomil provides better blood pressure control, reducing the need for add-on therapies. The efficacy advantage drives physician preference and prescription volume, supporting API demand.
2. Technical Challenge: Complex Synthesis and Impurity Control
The primary technical challenge for Azilsartan Medoxomil API is the complex multi-step synthesis and strict impurity control. Key impurities include: (a) azilsartan (de-esterified form – major impurity); (b) tetrazole isomers (regioisomers from tetrazole formation step); (c) dimer and oligomer impurities (from side reactions); (d) genotoxic impurities – alkylating agents (methyl iodide, ethyl iodide) used in synthesis must be controlled to <1.5 ppm (ICH M7 guideline). Regulatory authorities (FDA, EMA, NMPA) require: (i) impurity profiling (individual impurities <0.1%, total <0.5%); (ii) residual solvents testing (Class 1 solvents – benzene <2 ppm); (iii) heavy metals (Class 1 – As, Cd, Hg, Pb <10 ppm). Manufacturers must implement: (a) quality by design (QbD) – design space for critical process parameters; (b) process analytical technology (PAT) – in-process monitoring of reaction completion and impurity formation; (c) purification optimization – recrystallization and chromatography to achieve >99% purity. The high purity requirement (99%+) and genotoxic impurity control increase manufacturing cost and barrier to entry.
3. Industry Segmentation: Branded vs. Generic API, Regional Manufacturing
The Azilsartan Medoxomil API market segments by customer type and manufacturing geography.
Branded API (Takeda – Edarbi) – 40–45% of market value (declining). Takeda’s patent protection expired in major markets (US – 2021–2022; Europe – 2022; China – 2023). Branded API is now primarily for Takeda’s own formulation or for markets with extended data exclusivity.
Generic API – 55–60% of market value, fastest-growing (25–30% CAGR). Generic API suppliers (Lupin, Jubilant Pharma, Zhejiang Hongyuan, Honour Lab, HEC Pharm, Enomark, CTX Life Sciences, Zhejiang Tianyu, Zhuhai Rundu, Valiant Co) supply API to generic drug manufacturers (Teva, Sandoz, Mylan, Dr. Reddy’s, Cipla) for azilsartan medoxomil tablets.
China is the largest manufacturing hub for generic Azilsartan Medoxomil API (60–70% of generic API supply), leveraging lower production costs (labor, raw materials, utilities). India (Lupin, Jubilant Pharma) accounts for 20–25% of generic API supply. Europe and North America have limited API manufacturing (primarily branded).
4. Recent Market Developments (2025–2026)
- Lupin (October 2025) received FDA approval for its Abbreviated New Drug Application (ANDA) for azilsartan medoxomil tablets (20 mg, 40 mg, 80 mg), becoming the first generic azilsartan medoxomil product in the US market (launch January 2026). Lupin sources API from its own manufacturing facility in India.
- Zhejiang Hongyuan Pharmaceutical (November 2025) expanded its azilsartan medoxomil API production capacity from 20 tons/year to 50 tons/year, adding new purification and impurity control capabilities to meet increasing generic demand.
- Takeda (December 2025) announced discontinuation of branded Edarbi in the US market due to generic competition (Lupin entry), shifting focus to other cardiovascular products. Takeda will continue to supply API to licensees in select markets.
- FDA (January 2026) published a revised product-specific guidance for azilsartan medoxomil tablets, requiring bioequivalence studies with 80 mg strength (highest dose) and dissolution testing at pH 1.2, 4.5, and 6.8. The guidance standardizes generic development requirements.
- Chinese NMPA (February 2026) approved four additional domestic generic azilsartan medoxomil tablets (HEC Pharm, Zhejiang Tianyu, Zhuhai Rundu, Valiant Co), increasing competition and driving API demand.
5. Exclusive Observation: The Impact of Patent Expiry and Generic Entry
Azilsartan medoxomil patents expired in major markets during 2021–2023, but generic entry was delayed due to patent litigation (Takeda vs. generics) and formulation challenges (prodrug stability, dissolution profile). The first generic approval in the US (Lupin, October 2025) and subsequent approvals in China (2026) are driving rapid API volume growth. API demand is projected to increase from 50–60 tons in 2024 to 150–200 tons by 2028, as generics capture market share from branded Edarbi. API pricing pressure: branded API (US$5,000–8,000 per kg) vs. generic API (US$2,000–3,500 per kg). For API manufacturers, volume growth (20–25% CAGR) offsets price erosion. For generic drug manufacturers, azilsartan medoxomil represents a US$500–800 million market opportunity (branded sales were US$400–500 million annually pre-generic entry), with potential for 50–60% generic penetration by 2028.
Key Players
Takeda, Lupin, Acura Labs, Metrochem API, Jubilant Pharma, Zhejiang Hongyuan, Honour Lab, HEC Pharm, Enomark, CTX Life Sciences, Zhejiang Tianyu, Zhuhai Rundu, Valiant Co.
Strategic Takeaways for Pharmaceutical Manufacturers, API Suppliers, and Investors
- For generic drug manufacturers: Azilsartan medoxomil tablets (20/40/80 mg) are a high-value generic opportunity (US$500–800 million market) with limited competition (1–2 players initially, expanding to 5–10 by 2028). Key success factors: (a) API sourcing from qualified suppliers (>99% purity, genotoxic impurity control), (b) bioequivalence studies (80 mg strength, fed/fasted), (c) dissolution profile matching branded product (Edarbi).
- For API suppliers: Invest in azilsartan medoxomil API manufacturing capacity and impurity control capabilities. The generic API market is growing at 20–25% CAGR (2025–2028), with volume increasing from 50–60 tons to 150–200 tons. Differentiate through: (a) regulatory filings (DMF in US, Europe, China), (b) cost leadership (China-based manufacturing), (c) impurity profile (genotoxic impurities <1.5 ppm).
- For investors: The 20.0% CAGR for the overall market understates growth in the generic API subsegment (25–30% CAGR) and the Chinese API manufacturer subsegment (30–35% CAGR). Target companies with (a) DMF filings in major markets (FDA, EMA, NMPA), (b) manufacturing scale (>50 tons/year capacity), (c) impurity control capabilities (genotoxic impurities), and (d) backward integration into key intermediates (reducing raw material dependency). The growing adoption of generic antihypertensive drugs, especially in emerging markets, is boosting API production as countries aim to lower healthcare costs.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
